Table 3.
Total treatment numbers and SVR rates for Georgia's hepatitis C elimination programme, by level of liver disease
| No, mild, or moderate liver disease | Cirrhosis or decompensated cirrhosis | |
|---|---|---|
| May 1, 2015–Feb 29, 2016 | ||
| Total number treated | 2800* | 3779† |
| Per-protocol SVR | 1395/1564 (89·2%) | 2245/2960 (75·8%) |
| Intention to treat SVR | 1395/2228 (62·6%) | 2245/4346 (51·7%) |
| Adjusted SVR‡ | 1765/2201 (80·2%) | 2963/4057 (73·0%) |
| March, 2016–February, 2019 | ||
| Total number treated | 41 474§ | 6259¶ |
| Per-protocol SVR | 25 954/26 314 (98·6%) | 4497/4665 (96·4%) |
| Intention-to-treat SVR | 25 954/34 024 (76·3%) | 4497/6738 (66·7%) |
| Adjusted SVR‡ | 30 104/33 826 (89·0%) | 5573/6467 (86·2%) |
From May 1, 2015, to Feb 29, 2016, patients were treated with sofosbuvir-based (with or without ribavirin) regimens and from March 1, 2016, to Feb 28, 2019, they were treated with ledipasvir-sofosbuvir combination-based regimens. SVR=sustained virological response.
68 patients with no or mild liver disease and 2732 patients with moderate liver disease.
3757 patients with cirrhosis and 22 patients with decompensated cirrhosis.
The adjusted SVR assumes patients that completed treatment had the per-protocol SVR rate and that 55% of patients lost to follow up during treatment were cured on the basis of studies of shorter treatment regimens32 (appendix p 7).
21 608 patients with no or mild liver diseases and 19 866 with moderate liver disease.
5659 patients with cirrhosis and 601 patients with decompensated cirrhosis.